Gandomkar masoud - Dept. of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Rahmati Mohammad - Dept. of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Zarghami Nosratallah - Dept. of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
Darushnejad Hassan - Dept. of Medical Biotechnology, Faculty of Advance Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

Acute myeloid leukemia (AML) is a hematological malignancy that the cause of death in adults. In this cancer over expression of Bcl-2 and P-glycoprotein are the two cause of resistance. NF-κB, a transcription factor that enhance expression of the panel of gene, include the two mentioned above molecules. NF-κB is a good target for treatment of cancer and overcoming to drug resistance in cancer therapy. ABT-737 is a novel anti Bcl-2 small molecule drug that is has strong potency to chemotherapy as a new drug.

AML, HL 60, ABT-737,NBD peptide, mdr1